Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Alvotech And Stada Make Biosimilars Pact

Stada Gains Rights To Seven Biosimilars In Europe And Beyond

Executive Summary

Alvotech and Stada have struck a deal that will give Stada exclusive rights to sell seven Alvotech biosimilars “in all key European markets” as well as certain other territories.

You may also be interested in...



Stada And Alvotech Launch Higher-Strength Adalimumab In Europe

Stada and Alvotech have announced the launch of the Hukyndra higher-strength adalimumab biosimilar rival to Humira in selected European countries, with a wider roll-out to follow in the coming months.

Alvotech’s Ustekinumab Passes Safety And Efficacy Milestone

Alvotech has announced success in its confirmatory clinical safety and efficacy study for its AVT04 ustekinumab candidate, a proposed biosimilar to Stelara.

Alvotech Reveals Positive Data For Stelara Rival

Alvotech has reported positive results from a study for its AVT04 proposed biosimilar ustekinumab rival to Stelara. The news comes ahead of a key vote on Alvotech’s SPAC merger with Oaktree Capital Management that will take the company public.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB149328

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel